Esophageal Neoplasms, Squamous Cell Cancer
Conditions
Keywords
esophagectomy, chemotherapy, chemoradiotherapy, combined modality therapy
Brief summary
The purpose of the study was to test a null hypothesis that a combined modality treatment of esophageal cancer with neoadjuvant chemotherapy or chemoradiotherapy is equivalent to surgery alone and what are the benefits from adding irradiation to chemotherapy in neoadjuvant treatment of esophageal cancer.
Detailed description
The choice of the most beneficial method of treatment in esophageal cancer remains controversial and is the subject of vigorous debate. Surgery is still regarded as the principle modality among treatment strategies, with longterm survival achieved mainly in less advanced cases. More advanced cases, diagnosed more frequently, are more problematic in selection of the optimal therapeutic method. One of the options for improving treatment outcome in patients with advanced esophageal cancer is combined modality treatment with chemo- and chemoradiotherapy. Currently available RCTs have tested preoperative chemotherapy or chemoradiotherapy separately in comparison to surgery alone. Moreover, we do not know from these trials what is the added value of irradiation in a combined modality therapy over a preoperative chemotherapy. Another drawback of available RCTs is combining 2 different biological cancer entities: adenocarcinoma and squamous cell carcinoma of the esophagus as well as carcinoma of the esophagus and gastro-esophageal junction. That were the reasons for designing our trial testing 3 principal modes of esophageal cancer therapy: surgery vs. chemotherapy + surgery vs. chemoradiotherapy + surgery on homogenous population of esophageal cancer patients with single pathological type - squamous cell carcinoma affecting thoracic esophagus.
Interventions
PROCEDUREtransthoracic esophagectomy 2-field extended lymphadenectomy
right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
DRUGneoadjuvant chemotherapy (cisplatin, 5-fluorouracil)
21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
RADIATIONneoadjuvant chemoradiotherapy
21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
Sponsors
Ministry of Scientific Research and Information Technology, Poland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Informed consent * Histopathologically proven, clinically stage II-III (cTNM according to AJCC/UICC classification), primary squamous cell carcinoma of the thoracic esophagus * Patients' age above 18 years * General condition with Karnofsky performance status of \>70 * Circulatory and pulmonary capacity at normal range (FEV1 \>60%; FVC \>60%, NYHA I-II, cardiac output \>40%) * Normal function of the bone marrow (RBC \>3,5 T/l; PLT \>100 G/l) * Normal renal (creatinine \<1.5 of the upper limit) and liver (AST or ALT \<2,5 of the upper limit or bilirubin \<1,5 of the upper limit) function
Exclusion criteria
* Metastatic disease * Synchronous malignancy * History of other cancer within 5 years prior to esophageal cancer treatment * History of allergic reaction to cisplatin of 5-fluorouracil * Systemic infection * Pregnancy or female patients in childbearing age without proper contraceptives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mean, median, 1-year, 3-year, 5-year overall survival | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| toxicity-related morbidity and mortality | 30-day |
| postoperative morbidity and mortality | 30-day |
| clinical and pathological response rates | 60-day |
| curative resection rate | 30-day |
Countries
Poland
Outcome results
None listed